This story from CBS News teases readers with the promise of an at-home sperm test that may be as easy as a pregnancy test, yet readers aren’t given the basic information they need to understand the strengths and weaknesses of the research on the device.
Instead, the story focuses on the many unvetted possibilities of this device; it could “shake up the world of fertility testing” and it “could also potentially be used by men who have had a vasectomy to monitor their progress.”
Until this device is approved for these specific uses, this is speculation.
Sperm quality plays at least some role in about 50% all cases of infertility, according to the American Pregnancy Association. A story about a new at-home device for male infertility, therefore, is likely to be of high interest to many people. To avoid speculation, stories about research on the topic need to back away from what a device “could” do and focus more on what the research was actually capable of proving.
Only part of the prototype’s projected cost is discussed: $5 for a microchip device. While this sounds good, the cost of the “tiny weight scale” isn’t mentioned, nor is the “optical attachment” that could be 3D-printed. However, a consumer 3D printer can cost $1,000 or more, not including supplies.
Readers also are told male fertility screening is costly, but we’re never told what the cost is.
Readers are told each test is 98% accurate, but aren’t told where that number comes from or what it means.
Equally as important, the story doesn’t explain that sperm count is only one facet of fertility, at least as defined by the World Health Organization; motility, morphology, pH, and other factors are similarly important, though less frequent issues, and require more advanced testing to establish.
Potential harms aren’t discussed, and there’s a significant one: a man receiving a false-negative test (he believes his sperm count is too low, when it’s actually normal) or a false-positive (his sperm count is low, but a test tells him it’s normal) — and telling his partner this incorrect information. For a couple that’s trying desperately to conceive, that could be crushing news or deceptive false-hope. Any news story about a new screening test should discuss the false-negative and false-positive rates.
For example, a story at LiveScience captures these well, telling readers that about 98% of people with no training could detect abnormal sperm samples from a fertility clinic with the new device. The sensitivity of the test’s ability to actually detect a sample with a low sperm count was 99.3%, but only 89.4% of normal-sperm-count samples were correctly read by the device. This means more than 10% of men with a normal sperm count might be lead to believe their numbers are abnormal.
There’s mention of the device being a prototype–and a quick mention that the researchers are “refining” the test before seeking FDA approval. Yet other than that, there are few details to help readers discern the quality of the evidence. For example what needs to be refined before FDA approval? What were the limitations of this current study?
There’s no mongering or scary language here, and the story discusses the global prevalence of male infertility.
No independent sources were included, and the story didn’t disclose that the one source who was interviewed–researcher Hadi Shafiee–holds a patent on the technology.
Readers are not given any details on the obvious alternative–going to a clinic for testing, or using one of the other already-available at-home devices. These and other details aren’t addressed, and they’re important in establishing the significance of the new prototype device.
Readers are told the device is only in a prototype stage, implying it’s not yet for sale. More details could have been provided, but this is sufficient for a satisfactory rating.
The story takes the stance that this device is superior to others, stating the new prototype “could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes.” However, at least two at-home, relatively low-cost, and FDA-approved test kits are already on the market. SpermCheck is a simple chemical test that costs about $40-$50, for example, and The Trak is physical test that uses a miniature centrifuge and retails for about $200. Both achieve similar or greater reliability as the prototype described in the story.
And while the novelty of using a smartphone may be an attractive bell-and-whistle for some men, it’s not necessarily unique. For instance, The Trak has an app — though it doesn’t directly measure samples. (It instead functions as a log for tests and lifestyle guide to improve sperm count and help men conceive with their partners.)
The real novelty, as LiveScience’s story points out, is that smaller fertility clinics can’t afford semen analysis devices, which can cost between $50,000 and $100,000. They could, however, afford a smartphone-assisted device.
The talking points of this story and a news release by Brigham and Women’s Hospital match quite closely, but the story did include unique quotes not found in the news release, so this is a just-passing satisfactory.
Systematic, Criteria-Driven
FINALLY..... a commonsense analysis of yet more HYPE in the media about the next great hope for eliminating breast cancer. Thanks @mcjaklevic and @HealthNewsRevu. https://twitter.com/garyschwitzer/status/1192417365843206145
Here we go again: another “simple blood test" for early detection of breast cancer. News reports shout “CANCER BREAKTHROUGH” & other hype for preliminary, very limited findings. https://www.healthnewsreview.org/2019/11/theranos-redux-not-really-but-claim-of-a-simple-test-for-breast-cancer-warrants-scrutiny/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like